Why Popular Diabetes Drugs Like Ozempic Don’t Work for Everyone: The “Genetic Glitch”

A Stanford-led study suggests about 10% of people may have GLP-1 resistance.

PAM-related genetic variants can weaken the blood-sugar-lowering effect of drugs like Ozempic, Wegovy, and Mounjaro.

The effect appears to persist even when GLP-1 levels are high, pointing to a biological resistance in some patients.

The findings could help explain why these drugs work well for some people but not others and support more personalized treatment.

Researchers say genetic testing may eventually help match diabetes and weight-loss therapies to individual patients.